- Topline supports moving to Phase 3 trial and shows potential to develop GV1001 as the world's first PSP treatment SEOUL, South Korea , Oct. 29, 2024 /PRNewswire/ -- GemVax & KAEL Co., Ltd.
("GemVax"; KOSDAQ ticker: 082270) announced that topline results of a Phase 2a clinical trial (the "Phase 2a PSP Clinical Trial") of GV1001, an investigational peptide drug for the treatment of progressive supranuclear palsy ("PSP"), were presented at "Neuro2024: The PSP and CBD International Research Symposium" in Toronto, Canada , at 4:45 p.m. local time on 24 th October.
.
